Personal statement

I would support the technology of ACI, it is an established treatment with an excellent safety record. The literature supports ACI for the right indication and it is a technology that is required in the UK as we are currently restricted in our methods of treatment.

The ATMP regulation has resulted in a significant rise in the cost of cell therapies, which will potentially have an impact on local budgets. The recent socioeconomic data would support the use of ACI despite these increased costs. The ageing population is more active and consequently there is a need to try and delay early joint replacement surgery due to the inevitable and costly revision surgery that will result.

I would support the centralization of the therapy in order to ensure its most effective use. With limited centers commissioned, a better price can be negotiated based on volume, improving the health economics further and limiting the financial exposure of commissioning groups.